Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2Lymphoid 2Plasma cell 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 26Leukemia 21Lymphoma 17Leukemia, Myeloid, Acute 17Hodgkin Disease 16Multiple Myeloma 15Myeloproliferative Disorders 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Non-Hodgkin 12Leukemia, Lymphocytic, Chronic, B-Cell 11Congenital Abnormalities 10Lymphoma, Mantle-Cell 8Leukemia, Myeloid, Chronic-Phase 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Neoplasms, Plasma Cell 7Myelodysplastic-Myeloproliferative Diseases 7Lymphoma, Large-Cell, Immunoblastic 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Lymphoma, B-Cell, Marginal Zone 7Burkitt Lymphoma 7Primary Myelofibrosis 6Leukemia, Myelomonocytic, Chronic 6Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 6Leukemia, Myeloid, Accelerated Phase 6Blast Crisis 6Anemia, Aplastic 6Graft vs Host Disease 5Waldenstrom Macroglobulinemia 4Recurrence 4

Interventions

Cyclophosphamide 10fludarabine 8Mycophenolic Acid 7Tacrolimus 6Melphalan 6ruxolitinib 5fludarabine phosphate 5Imatinib Mesylate 5Busulfan 5Bone Marrow Transplantation 5ponatinib 4Mesna 4Azacitidine 4nilotinib 3Whole-Body Irradiation 3Thiotepa 3Stem Cell Transplantation 3Granulocyte Colony-Stimulating Factor 3Cyclosporine 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3lintuzumab 2Vorinostat 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methotrexate 2Filgrastim 2Alemtuzumab 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2vosaroxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hematologic Diseases × Alemtuzumab × Myeloid × Clear all
NCT01191749 2017-05-09

Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)

M.D. Anderson Cancer Center

Phase 2 Terminated
7 enrolled 6 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Aplastic, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Large Granular Lymphocytic

NCT00579111 2016-05-04

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

Baylor College of Medicine

Phase 1/2 Terminated
4 enrolled 8 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Lymphoproliferative Disorders, Multiple Myeloma, Myeloproliferative Disorders, Paraproteinemias, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡